Non-invasive Prediction of EArly Cardiac rEjection
for Heart Transplant
Sites in Nashville +21 more locations
Sponsor: Vanderbilt University Medical Center
Sex: All·Age: 6 - 25
Code: NCT07770659·Recruiting·Listed Aug 18, 2026
Clinical Trials at Vanderbilt University Medical Center
As of September 2026, 318 paid clinical trials are recruiting at Vanderbilt University Medical Center, located at 1215 21ST AVE S, SUITE 9302, NASHVILLE, TN 37232-0014, phone (615) 343-6152 in Nashville, Tennessee. Active studies at this site cover conditions such as Breast Cancer, Colorectal Cancer and Advanced Solid Tumor. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Filter results
Newly added in Nashville
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
for Symptomatic Genetic Dilated Cardiomyopathy (DCM)
Sites in Nashville +27 more locations
Sponsor: Kardigan, Inc.
Sex: All·Age: 18+
Code: NCT07771465·Phase 3·Recruiting·Listed Aug 18, 2026
320 clinical trials at Vanderbilt University Medical Center
·Clear filters· Get a weekly email when new trials open in Nashville, TN.
Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
for HIV Infections
Sites in Nashville +37 more locations
Sponsor: Gilead Sciences
Sex: All·Age: 18+
Code: NCT07473778·Recruiting·Listed Mar 2026
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
for Parkinson Disease
Sites in Nashville +29 more locations
Sponsor: Appello Pharmaceuticals, Inc.
Sex: All·Age: 30 - 80
Code: NCT07432958·Phase 2·Recruiting·Listed Feb 2026
Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)
for Hepatitis
Drug: Larsucosterol
Sites in Nashville, Chattanooga +83 more locations
Sponsor: Bausch Health Americas, Inc.
Sex: All·Age: 18+
Code: NCT07428538·Phase 3·Recruiting·Listed Feb 2026
A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older
for Clostridoides Difficile Associated Disease
Sites in Nashville, Knoxville +138 more locations
Sponsor: Pfizer
Sex: All·Age: 65+·Accepts healthy volunteers
Code: NCT07282665·Phase 3·Recruiting·Listed Dec 2025
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
for Squamous Cell Carcinoma of Head and Neck
Drug: Amivantamab
Sites in Nashville, Knoxville +45 more locations
Sponsor: Janssen Research & Development, LLC
Sex: All·Age: 18+
Code: NCT07276399·Phase 3·Recruiting·Listed Dec 2025
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
for Metabolic Dysfunction Associated Steatohepatitis (MASH)
Drug: Survodutide
Sites in Nashville, Clarksville +161 more locations
Sponsor: Boehringer Ingelheim
Sex: All·Age: 18+
Code: NCT06632444·Phase 3·Recruiting·Listed Oct 2024
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
for Metabolic Dysfunction Associated Steatohepatitis
Drug: Survodutide
Sites in Nashville, Clarksville +124 more locations
Sponsor: Boehringer Ingelheim
Sex: All·Age: 18+
Code: NCT06632457·Phase 3·Recruiting·Listed Oct 2024
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
for End Stage Kidney Disease
Drug: Clazakizumab
Sites in Nashville, Chattanooga +147 more locations
Sponsor: CSL Behring
Sex: All·Age: 18+
Code: NCT05485961·Phase 2, Phase 3·Recruiting·Listed Aug 2022
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
for Ovarian Neoplasms
Sites in Nashville +85 more locations
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT07213804·Phase 3·Recruiting·Listed Oct 2025
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
for Multiple Myeloma
Sites in Nashville +38 more locations
Sponsor: Janssen Research & Development, LLC
Sex: All·Age: 18+
Code: NCT07258511·Phase 3·Recruiting·Listed Dec 2025
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
for Colorectal Neoplasms
Drug: Amivantamab
Sites in Nashville, Chattanooga +66 more locations
Sponsor: Janssen Research & Development, LLC
Sex: All·Age: 18+
Code: NCT06750094·Phase 3·Recruiting·Listed Dec 2024
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
for Clostridium Difficile
Sites in Nashville, Cordova +54 more locations
Sponsor: Vedanta Biosciences, Inc.
Sex: All·Age: 12+
Code: NCT06237452·Phase 3·Recruiting·Listed Feb 2024
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
for Breast Cancer
Sites in Nashville, Germantown +59 more locations
Sponsor: Hoffmann-La Roche
Sex: All·Age: 18+
Code: NCT06790693·Phase 3·Recruiting·Listed Jan 2025
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
for Large B-cell Lymphoma
Sites in Nashville +60 more locations
Sponsor: Allogene Therapeutics
Sex: All·Age: 18+
Code: NCT06500273·Phase 2·Recruiting·Listed Jul 2024
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
for Metastatic Colorectal Cancer
Sites in Nashville +19 more locations
Sponsor: Hoffmann-La Roche
Sex: All·Age: 18+
Code: NCT04929223·Phase 1·Recruiting·Listed Jun 2021
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
for Oligometastatic Prostate Cancer (OMPC)
Sites in Nashville +36 more locations
Sponsor: Novartis Pharmaceuticals
Sex: Male·Age: 18 - 100
Code: NCT05939414·Phase 3·Recruiting·Listed Jul 2023
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
for Parkinson's Disease
Drug: Prasinezumab
Sites in Nashville, Memphis +51 more locations
Sponsor: Hoffmann-La Roche
Sex: All·Age: 50 - 85
Code: NCT07174310·Phase 3·Recruiting·Listed Sep 2025
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
for Mitral Valve Regurgitation
Sites in Nashville +68 more locations
Sponsor: Medtronic Cardiovascular
Sex: All·Age: 18+
Code: NCT03242642·Recruiting·Listed Aug 2017
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
for Chronic Kidney Disease
Drug: Empagliflozin
Sites in Nashville +11 more locations
Sponsor: Boehringer Ingelheim
Sex: All·Age: 2 - 17
Code: NCT07107945·Phase 3·Recruiting·Listed Aug 2025
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
for Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
Drug: zolbetuximab
Sites in Nashville, Knoxville +35 more locations
Sponsor: Astellas Pharma Global Development, Inc.
Sex: All·Age: 18+
Code: NCT06901531·Phase 3·Recruiting·Listed Mar 2025
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
for Urinary Bladder Neoplasms
Sites in Nashville +40 more locations
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT05614739·Phase 1·Recruiting·Listed Nov 2022
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
for Focal Epilepsy
Drug: BHV-7000
Sites in Nashville +44 more locations
Sponsor: Biohaven Therapeutics Ltd.
Sex: All·Age: 18 - 75
Code: NCT06132893·Phase 2, Phase 3·Recruiting·Listed Nov 2023
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
for Venous Thromboembolism
Sites in Nashville +32 more locations
Sponsor: Inari Medical
Sex: All·Age: 18+
Code: NCT05701917·Recruiting·Listed Jan 2023
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
for Moderately to Severely Active Crohns Disease
Drug: Afimkibart
Sites in Nashville, Cordova +57 more locations
Sponsor: Hoffmann-La Roche
Sex: All·Age: 16 - 80
Code: NCT06819891·Phase 3·Recruiting·Listed Feb 2025
ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve
for Aortic Stenosis, Severe
Sites in Nashville +25 more locations
Sponsor: Edwards Lifesciences
Sex: All·Age: All ages
Code: NCT05172960·Recruiting·Listed Dec 2021
A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
for Lung Transplant Rejection
Sites in Nashville +31 more locations
Sponsor: Sanofi
Sex: All·Age: 18+
Code: NCT06082037·Phase 3·Recruiting·Listed Oct 2023
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
for Metastatic Colorectal Cancer
Drug: Bevacizumab
Sites in Nashville +10 more locations
Sponsor: Amgen
Sex: All·Age: 18+
Code: NCT06252649·Phase 3·Recruiting·Listed Feb 2024
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
for Heart Failure
Sites in Nashville, Tullahoma +79 more locations
Sponsor: Cytokinetics
Sex: All·Age: 18 - 85
Code: NCT06736574·Phase 3·Recruiting·Listed Dec 2024
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
for cGVHD
Sites in Nashville +30 more locations
Sponsor: Incyte Corporation
Sex: All·Age: 18+
Code: NCT05919511·Recruiting·Listed Jun 2023
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
for AML
Sites in Nashville +35 more locations
Sponsor: Kura Oncology, Inc.
Sex: All·Age: 18+
Code: NCT06001788·Phase 1·Recruiting·Listed Aug 2023
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
for Relapsed Non-Hodgkin Lymphoma
Sites in Nashville +31 more locations
Sponsor: Lyell Immunopharma, Inc.
Sex: All·Age: 18+
Code: NCT05826535·Phase 1, Phase 2·Recruiting·Listed Apr 2023
A Study of Patients With Lower Extremity Acute Limb Ischemia to Remove Thrombus With the Indigo™ Aspiration System (STRIDE II)
for Lower Extremity Acute Limb Ischemia
Sites in Nashville, Jackson +32 more locations
Sponsor: Penumbra Inc.
Sex: All·Age: 18+
Code: NCT06747117·Recruiting·Listed Dec 2024
A Study of ASP3082 in Adults With Advanced Solid Tumors
for Solid Tumor
Sites in Nashville +24 more locations
Sponsor: Astellas Pharma Inc
Sex: All·Age: 18+
Code: NCT05382559·Phase 1·Recruiting·Listed May 2022
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
for Progressive Pulmonary Fibrosis
Sites in Nashville +26 more locations
Sponsor: Avalyn Pharma Inc.
Sex: All·Age: 18+
Code: NCT06951217·Phase 2·Recruiting·Listed Apr 2025
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
for Colorectal Cancer
Sites in Nashville, Memphis +30 more locations
Sponsor: Takeda
Sex: All·Age: 18+
Code: NCT06562543·Phase 4·Recruiting·Listed Aug 2024
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
for Parkinsons Disease (PD)
Sites in Nashville +33 more locations
Sponsor: BlueRock Therapeutics
Sex: All·Age: 45 - 75
Code: NCT06944522·Phase 3·Recruiting·Listed Apr 2025
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
for Moderate Aortic Valve Stenosis
Drug: Ataciguat
Sites in Nashville +68 more locations
Sponsor: Kardigan, Inc.
Sex: All·Age: 50+
Code: NCT07001800·Phase 2, Phase 3·Recruiting·Listed Jun 2025
Pan Tumor Rollover Study
for Cancer
Sites in Nashville +6 more locations
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 18+
Code: NCT03899155·Phase 2·Recruiting·Listed Apr 2019
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
for Acute Respiratory Distress Syndrome (ARDS)
Sites in Nashville +39 more locations
Sponsor: PPD Development, LP
Sex: All·Age: 18+
Code: NCT06703073·Phase 2·Recruiting·Listed Nov 2024
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
for Acute Respiratory Distress Syndrome (ARDS)
Drug: Bevacizumab
Sites in Nashville +39 more locations
Sponsor: PPD Development, LP
Sex: All·Age: 18+
Code: NCT06701656·Phase 2·Recruiting·Listed Nov 2024
Common conditions studied in Nashville
- Breast Cancer (40 active studies)
- Colorectal Cancer (33 active studies)
- Advanced Solid Tumor (30 active studies)
- Ovarian Cancer (29 active studies)
- Prostate Cancer (25 active studies)
- Endometrial Cancer (23 active studies)
Leading research sponsors in Nashville
- Vanderbilt University Medical Center
- AstraZeneca
- Vanderbilt-Ingram Cancer Center
- National Cancer Institute (NCI)
- Eli Lilly and Company
Frequently asked questions
How many paid clinical trials are currently recruiting in Nashville?
There are approximately 1,346 recruiting clinical trials in Nashville, Tennessee listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Nashville pay participants?
Most recruiting trials in Nashville compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Nashville?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Nashville?
The most common conditions under active study in Nashville include Breast Cancer (40), Colorectal Cancer (33), Advanced Solid Tumor (30), Ovarian Cancer (29), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Nashville?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Nashville on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Nashville?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Nashville?
Recruiting research sites in Nashville include Vanderbilt University Medical Center, SCRI Oncology Partners, Vanderbilt University/Ingram Cancer Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Nashville right now?
The largest active categories in Nashville are Cancer & tumors (553), Cardiovascular (91), Neurology & pain (63). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Vanderbilt University Medical Center?
Vanderbilt University Medical Center is located at 1215 21ST AVE S, SUITE 9302, NASHVILLE, TN 37232-0014. Use the Google Maps link in the intro above to get directions.
How do I contact Vanderbilt University Medical Center?
You can reach Vanderbilt University Medical Center by phone at (615) 343-6152. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.
Browse more clinical trials
Other cities in Tennessee
Memphis, TN(453)Knoxville, TN(217)Chattanooga, TN(126)Germantown, TN(96)Jackson, TN(44)Collierville, TN(43)Franklin, TN(32)Kingsport, TN(31)Cordova, TN(30)Murfreesboro, TN(24)Johnson City, TN(22)Smyrna, TN(14)Tullahoma, TN(14)Hermitage, TN(9)Mount Juliet, TN(8)Oak Ridge, TN(8)Brentwood, TN(7)Bristol, TN(7)Clarksville, TN(7)Cleveland, TN(7)Hendersonville, TN(7)Shelbyville, TN(7)Bartlett, TN(6)Lebanon, TN(6)Cookeville, TN(5)Crossville, TN(5)Gallatin, TN(5)Hixson, TN(5)Jefferson City, TN(5)Powell, TN(5)Dickson, TN(4)Greeneville, TN(4)Morristown, TN(4)Columbia, TN(3)Mountain Home, TN(3)Nashvile, TN(3)Goodlettsville, TN(2)Maryville, TN(2)Tennessee City, TN(2)Winchester, TN(2)Alcoa, TN(1)Harriman, TN(1)Lenoir City, TN(1)Mephis, TN(1)Nasville, TN(1)Sevierville, TN(1)Spring Hill, TN(1)